Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published

Arcutis Biotherapeutics (ARQT) announced that the American Journal of Clinical Dermatology published data from the Phase 2 long-term safety open-label extension study that demonstrated once-daily ZORYVE foam 0.3% is safe, well-tolerated, and efficacious for up to 52 weeks of treatment in individuals with seborrheic dermatitis. ZORYVE foam was approved in December 2023 by the U.S. Food & Drug Administration for the topical treatment of seborrheic dermatitis in adults and adolescents 9 years of age and older; in 2025 it was also approved for the topical treatment of scalp and body plaque psoriasis in adults and adolescents 12 years of age and older and is available in pharmacies nationwide. The primary endpoint was safety. Treatment-Emergent Adverse Events were reported for 130 participants. The most common TEAE was COVID-19, which was reported for 15 participants, followed by headache in 13 participants. Serious Adverse Events were reported for 7 individuals, none of which were considered treatment related. Overall, 5 of 400 participants discontinued the trial because of an AE.